Natel Neutratec (India) Pvt. Ltd.

Clinical Trials

ANBUTA PLUS – safety, toxicity, mutagenicity, and mitogenicity tests


UNIVERSIDADE FEDERAL DO PARANA
LABORATORIO DE PESQUISA EM CELULAS
INFLAMATORIAS E NEO PLASICAS

S.C.B - Departmento De Biologia Celular
Centro Politecnico - CEP 81531-970
Curitiba - Parana
Tel. : (41) 3361-1770, 3361-1682 Fax : 3361-1568
E-mail : buchi@urpr.br & labbiocel@urpr.br

It was analyzed the toxicity of MODUL8 (ANBUTA PLUS) with K562 (immortalized from human myelogenous leukemia) by flow citometry. It was used the kit from BIOPharmigen, Annexin V-FITC Apoptosis Detection, and it was also used Propidium Iodide (PI) to evaluate cell viability and DNA content in cell cycle. PI is an intercalating DNA agent and a fluorescent molecule. All experiments were performed at least three times, and data, representative of three independent experiments, was performed in a double-bind manner with ANOVA and Tukey test.

Table with results about apoptosis and cell viability of k-562 cell line after modul8 treatment (*p<0,05)

Viable Necrosis Early apoptosis Late apoptosis
Control 85,705 11,00667 0,826667 2,456667
Hidro-alcoholic solution 85,22167 11,74167 1,126667 1,91
Modul8 87,46333 9,128333 1,281667 2,126667

The percentage of viable cells is about 85% and there is no significance between groups after treatment.

There is no difference between G1, S and G2 phases of cell cycle between treated and control cells.

Conclusion: The medication does not interfere in cell cycle, does not damage DNA molecule and does not induce apoptosis. Briefly, it is neither toxic, nor mitogenic, or mutagenic.

Natel Neutratec (India) Pvt. Ltd.